WO2006009887A3 - Evaluation of brain treatment - Google Patents

Evaluation of brain treatment Download PDF

Info

Publication number
WO2006009887A3
WO2006009887A3 PCT/US2005/021557 US2005021557W WO2006009887A3 WO 2006009887 A3 WO2006009887 A3 WO 2006009887A3 US 2005021557 W US2005021557 W US 2005021557W WO 2006009887 A3 WO2006009887 A3 WO 2006009887A3
Authority
WO
WIPO (PCT)
Prior art keywords
persons
disease
risk
change
treated
Prior art date
Application number
PCT/US2005/021557
Other languages
French (fr)
Other versions
WO2006009887A2 (en
Inventor
Eric M Reiman
Original Assignee
Banner Health
Eric M Reiman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banner Health, Eric M Reiman filed Critical Banner Health
Priority to CA002570539A priority Critical patent/CA2570539A1/en
Priority to EP05772647A priority patent/EP1761191A4/en
Priority to MXPA06014611A priority patent/MXPA06014611A/en
Publication of WO2006009887A2 publication Critical patent/WO2006009887A2/en
Publication of WO2006009887A3 publication Critical patent/WO2006009887A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Abstract

For real persons at risk for Alzheimer's disease, a neurodegenerative disease, or brain aging, a measurement's rate of change can be characterized during or following the real persons' treatment with disease-preventing or neurological age-slowing therapy. For hypothetical persons similar to the real persons at risk for these conditions but who are not so treated, the measurement's rate of change can be characterized over a like time interval. The disease-­preventing or age-slowing therapy's efficacy is suggested by a smaller measurement rate of change over the like time interval in the real persons treated than in the hypothetical persons not so treated, even in the absence of clinical decline over the time interval. Measurements of neurodegenerative disease progression will have significantly higher rates of change in persons clinically affected by or at risk for the disease than in those persons at lower risk for the neurodegenerative disease.
PCT/US2005/021557 2004-06-18 2005-06-17 Evaluation of brain treatment WO2006009887A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002570539A CA2570539A1 (en) 2004-06-18 2005-06-17 Evaluation of a treatment to decrease the risk of a progressive brain disorder or to slow brain aging
EP05772647A EP1761191A4 (en) 2004-06-18 2005-06-17 Evaluation of a treatment to decrease the risk of a progeressive brain disorder or to slow brian aging
MXPA06014611A MXPA06014611A (en) 2004-06-18 2005-06-17 Evaluation of brain treatment.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58076204P 2004-06-18 2004-06-18
US60/580,762 2004-06-18

Publications (2)

Publication Number Publication Date
WO2006009887A2 WO2006009887A2 (en) 2006-01-26
WO2006009887A3 true WO2006009887A3 (en) 2006-12-21

Family

ID=35785713

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/021557 WO2006009887A2 (en) 2004-06-18 2005-06-17 Evaluation of brain treatment

Country Status (5)

Country Link
US (1) US20050283054A1 (en)
EP (1) EP1761191A4 (en)
CA (1) CA2570539A1 (en)
MX (1) MXPA06014611A (en)
WO (1) WO2006009887A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2353795A1 (en) * 1998-12-02 2000-06-08 The Trustees Of The University Of Pennsylvania Methods and compositions for determining lipid peroxidation levels in oxidant stress syndromes and diseases
US9492114B2 (en) 2004-06-18 2016-11-15 Banner Health Systems, Inc. Accelerated evaluation of treatments to prevent clinical onset of alzheimer's disease
US9471978B2 (en) 2004-10-04 2016-10-18 Banner Health Methodologies linking patterns from multi-modality datasets
WO2007114238A1 (en) * 2006-03-30 2007-10-11 National University Corporation Shizuoka University Apparatus for determining brain atrophy, method of determining brain atrophy and program for determining brain atrophy
CA2655126A1 (en) * 2006-06-21 2007-12-27 Lexicor Medical Technology, Llc Systems and methods for analyzing and assessing dementia and dementia-type disorders
JP5319121B2 (en) 2007-01-30 2013-10-16 株式会社東芝 Medical support system and medical support device
DE102007034956A1 (en) * 2007-07-26 2009-02-05 Siemens Ag Method for detecting a neuropathologically altered brain region
US9211077B2 (en) * 2007-12-13 2015-12-15 The Invention Science Fund I, Llc Methods and systems for specifying an avatar
US20090157625A1 (en) * 2007-12-13 2009-06-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for identifying an avatar-linked population cohort
US8356004B2 (en) * 2007-12-13 2013-01-15 Searete Llc Methods and systems for comparing media content
US8615479B2 (en) * 2007-12-13 2013-12-24 The Invention Science Fund I, Llc Methods and systems for indicating behavior in a population cohort
US20090156955A1 (en) * 2007-12-13 2009-06-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for comparing media content
US20090157660A1 (en) * 2007-12-13 2009-06-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems employing a cohort-linked avatar
US20090157751A1 (en) * 2007-12-13 2009-06-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for specifying an avatar
US8195593B2 (en) * 2007-12-20 2012-06-05 The Invention Science Fund I Methods and systems for indicating behavior in a population cohort
US20090164302A1 (en) * 2007-12-20 2009-06-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for specifying a cohort-linked avatar attribute
US20090157481A1 (en) * 2007-12-13 2009-06-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for specifying a cohort-linked avatar attribute
US20090164458A1 (en) * 2007-12-20 2009-06-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems employing a cohort-linked avatar
US9418368B2 (en) * 2007-12-20 2016-08-16 Invention Science Fund I, Llc Methods and systems for determining interest in a cohort-linked avatar
US8150796B2 (en) * 2007-12-20 2012-04-03 The Invention Science Fund I Methods and systems for inducing behavior in a population cohort
US9775554B2 (en) * 2007-12-31 2017-10-03 Invention Science Fund I, Llc Population cohort-linked avatar
WO2009146388A1 (en) 2008-05-28 2009-12-03 The Trustees Of Columbia University In The City Of New York Voxel-based methods for assessing subjects using positron emission tomography
US9805473B2 (en) * 2008-09-19 2017-10-31 Siemens Healthcare Gmbh Method and system for segmentation of brain structures in 3D magnetic resonance images
EP2401617A4 (en) * 2009-02-24 2012-09-26 Winton G Gibbons Detection of complexes of tau and amyloid
US9025841B2 (en) * 2009-11-18 2015-05-05 Siemens Aktiengesellschaft Method and system for segmentation of the prostate in 3D magnetic resonance images
DE102011085404A1 (en) * 2011-10-28 2013-05-02 Siemens Aktiengesellschaft Method for measuring structures of the human brain
US9510756B2 (en) * 2012-03-05 2016-12-06 Siemens Healthcare Gmbh Method and system for diagnosis of attention deficit hyperactivity disorder from magnetic resonance images
WO2015060317A1 (en) * 2013-10-22 2015-04-30 長谷川亨 Neurodegenerative disease testing method
US11885816B2 (en) * 2013-11-26 2024-01-30 University Of North Texas Health Science Center At Forth Worth Personalized medicine approach for treating cognitive loss
US9721316B2 (en) * 2014-01-10 2017-08-01 Bank Of America Corporation Change convergence risk mapping
US10851416B2 (en) 2014-06-24 2020-12-01 Likeminds, Inc. Predictive neurodiagnostic methods
CN105046709B (en) * 2015-07-14 2018-06-29 华南理工大学 A kind of brain age analysis method based on nuclear magnetic resonance image
KR102487839B1 (en) * 2016-02-04 2023-01-12 리제너론 파마슈티칼스 인코포레이티드 Non-human animals with an engineered ANGPTL8 gene
WO2018194778A1 (en) * 2017-04-18 2018-10-25 University Of Florida Research Foundation, Inc. Diffusion imaging in parkinson's disease and parkinsonism
US20200166525A1 (en) * 2017-07-25 2020-05-28 Toru Hasegawa Diagnosis-aiding method for determining neurodegenerative disease
EP3704712A1 (en) * 2017-10-31 2020-09-09 GE Healthcare UK Limited Medical system for diagnosing cognitive disease pathology and/or outcome
CN108830830A (en) * 2018-05-11 2018-11-16 深圳博脑医疗科技有限公司 A kind of quantitative detecting method of brain atrophy, detection device and terminal device
CN109543623B (en) * 2018-11-26 2021-01-29 微医云(杭州)控股有限公司 Fetus development condition prediction device based on nuclear magnetic resonance imaging
CN113507881A (en) * 2018-12-10 2021-10-15 牛津大学创新有限公司 Brain imaging
CN111134677B (en) * 2020-02-14 2021-05-04 北京航空航天大学 Magnetic resonance image-based stroke-induced disability prediction method and system
CA3221182A1 (en) * 2021-06-29 2023-01-05 Wen-Yih Tseng Method of evaluating concomitant clinical dementia rating and its future outcome using predicted age difference and program thereof
CN115018836A (en) * 2022-08-08 2022-09-06 四川大学 Automatic dividing and predicting method, system and equipment for epileptic focus
CN117275734A (en) * 2023-11-20 2023-12-22 苏州药明泽康生物科技有限公司 Brain health state assessment method and device

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5617861A (en) * 1994-02-16 1997-04-08 Huntington Medical Research Institutes Magnetic resonance spectral analysis of the brain for diagnosis of clinical conditions
US7239908B1 (en) * 1998-09-14 2007-07-03 The Board Of Trustees Of The Leland Stanford Junior University Assessing the condition of a joint and devising treatment
US6664961B2 (en) * 2000-12-20 2003-12-16 Rutgers, The State University Of Nj Resample and composite engine for real-time volume rendering
US6488221B1 (en) * 2001-05-25 2002-12-03 Maxtec, Inc. Self-aligning, spring-disk waterjet assembly
US7483557B2 (en) * 2003-09-30 2009-01-27 Kabushiki Kaisha Toshiba Medical imaging communication system, method and software
US20050209785A1 (en) * 2004-02-27 2005-09-22 Wells Martin D Systems and methods for disease diagnosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REIMAN E.M. ET AL.: "Declining brain activity in cognitively normal apolipoprotein E epsilon4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease", PNAS, vol. 98, no. 6, 13 March 2001 (2001-03-13), pages 3334 - 3339, XP003001343 *

Also Published As

Publication number Publication date
CA2570539A1 (en) 2006-01-26
WO2006009887A2 (en) 2006-01-26
MXPA06014611A (en) 2008-03-11
US20050283054A1 (en) 2005-12-22
EP1761191A4 (en) 2008-05-14
EP1761191A2 (en) 2007-03-14

Similar Documents

Publication Publication Date Title
WO2006009887A3 (en) Evaluation of brain treatment
WO2006107814A3 (en) Methods for measuring the metabolism of neurally derived biomolecules in vivo
HK1092367A1 (en) Combination therapy for the treatment of ocular neovascular disorders
WO2005076819A3 (en) Chlorite in the treatment of neurodegenerative disease
IL230241A (en) Retinal derivatives and methods for the use thereof for the treatment of visual disorders
PT2527315E (en) Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes and parkinson's disease
AU2002252373A1 (en) Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
TW200730525A (en) Therapeutic agents
WO2007061750A3 (en) Adipose tissue derived stromal cells for the treatment of neurological disorders
EP1945628A4 (en) New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease
IL220065A0 (en) Methods of preventing, treating and diagnosing disorders of protein aggregation
IL174475A0 (en) 1,1,1-trifluoro-4-phenyl-4-methyl-2-(1h-pyrrolo['2,3-c]pyridin-2-ylmethyl)pentan-2-ol derivatives and related compounds as glucocorticoid ligands for the treatment of inflammatory diseases and diabetes
MX2010003667A (en) Alkoxy compounds for disease treatment.
PT1594833E (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
WO2004074243A3 (en) Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
IL163752A0 (en) Use of epothilones in the treatment of brain diseases associated with proliferative processes
WO2006105530A3 (en) Use of eeg to measure cerebral changes during computer-based motion sickness-inducing tasks
WO2008086452A3 (en) Treatment and prevention of alzheimer's disease
WO2001058476A3 (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
WO2008157747A8 (en) Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders
WO2006121995A3 (en) Methods for treating nephrolithiasis
WO2004063340A3 (en) Methods and compositions for treating cardiovascular disease using 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061,17662,1468,12282, 6350, 9035,1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123,12788,17729, 65552,1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 4
GB0701177D0 (en) Agents and methods for early diagnosis and monitoring of alzheimer's disease and other neurological disorders
WO2005046605A3 (en) Compositions and methods of treating neurological diseases
WO2004110354A3 (en) Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2005772647

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2570539

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/014611

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007516799

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 139/KOLNP/2007

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2005772647

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP